Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma

Table 5 Multivariate Cox regression analysis based on overall survival

Variable	HR	Overall survival, 95%CI	P value
Model 1
NLR > 3.89	1.603	0.789-3.257	0.192
CTC PD-L1 (+) > 1	5.381	2.581-11.215	< 0.001
Liver cirrhosis (positive)	1.251	0.693-2.258	0.457
ALBI grade			0.347
1
2	1.149	0.631-2.095	0.649
3	2.352	0.743-7.442	0.146
AFP ≥ 400ng/mL	2.410	1.323-4.390	0.004
Model 2
CTC-NLR			< 0.001
0
1	2.684	1.187-6.070	0.018
2	8.470	3.957-18.129	0.000
Liver cirrhosis (positive)	1.261	0.697-2.282	0.442
ALBI grade			0.218
1
2	1.191	0.653-2.171	0.569
3	2.739	0.884-8.489	0.081
AFP ≥ 400ng/mL	2.096	1.180-3.723	0.012

NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell; ALBI: Albumin–bilirubin; AFP: Alpha-fetoprotein; HR: Hazard ratio; 95%CI: 95% confidence interval.